SURG-27 COMPLETE RESECTION OF CONTRAST ENHANCING TUMOR VOLUME IS ASSOCIATED WITH IMPROVED SURVIVAL IN RECURRENT GLIOBLASTOMA - RESULTS FROM THE DIRECTOR TRIAL

Similar Items

• Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma—results from the DIRECTOR trial
  od: Suchorska, Bogdana, i dr.
  Izdano: (2016)
• ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL
  od: Wirsching, Hans-Georg, i dr.
  Izdano: (2018)
• P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial
  od: Vils, A., i dr.
  Izdano: (2017)
• NIMG-54. DIFFUSE TUMOR GROWTH PATTERN IS ASSOCIATED WITH WORSE OUTCOME ONLY IN IDH WILDTYPE BUT NOT IN IDH MUTANT GLIOMAS WHO II AND III
  od: Weller, Jonathan, i dr.
  Izdano: (2020)
• AI-28 RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB
  od: Tabatabai, Ghazaleh, i dr.
  Izdano: (2014)